Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Hydroxyzine

Plain-language summaryIntrigue 56 / 100

Hydroxyzine (Atarax, Vistaril) is a first-generation antihistamine from UCB, approved in 1956, that crosses the blood-brain barrier readily and produces sedation and anxiolysis as a result. It is FDA-approved for anxiety and pruritus (itching), and unlike benzodiazepines it has no dependence or withdrawal potential, which makes it a useful first-line option for situational anxiety in patients with substance use histories. The trade-off is that the same antihistamine and anticholinergic effects produce dry mouth, constipation, urinary retention, and next-day grogginess. The active leftover after liver metabolism is cetirizine (Zyrtec), the over-the-counter allergy drug, which does not cross into the brain at clinical doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A 1956-approved FDA drug with solid clinical evidence and essentially no research frontier left to explore

Look, hydroxyzine is a real drug. FDA approved in 1956, over a billion patient-exposures, solid randomized data for generalized anxiety and pruritus, a clean non-scheduled status that made it clinically useful before buspirone or the SSRIs arrived. We’re not dismissing it clinically. We’re saying there’s almost nothing here for a bench investigator in 2026 that hasn’t been settled for decades.

The mechanism is H1 antagonism at roughly 2 nM affinity, secondary 5-HT2A blockade around 10 nM, and a weak D2 component. That multi-receptor fingerprint is interesting in the abstract, but it’s fully mapped, well-understood, and not pointing at anything new. The 5-HT2A angle doesn’t give you psychoplastogen biology; the D2 component isn’t the basis for a new antipsychotic story. You’re reading 1980s receptor binding papers when you go looking for mechanism literature here.

What’s genuinely useful about hydroxyzine as a research tool is the metabolite relationship. Hydroxyzine produces cetirizine in vivo, and cetirizine loses CNS penetration because of the carboxylic acid group. That pairing has been used as a probe model to interrogate what H1-mediated CNS penetration actually contributes versus peripheral H1 blockade. Thats a narrow but real utility. If you’re building a pharmacokinetic or CNS-penetration model around first-generation antihistamines, hydroxyzine earns a seat at the table. For anything else, it doesn’t.

The evidence base is strong by the standards of research compounds. Multiple replicated RCTs across anxiety and pruritus indications, decent Hamilton Anxiety Rating Scale data, perioperative sedation trials. The HAMA studies from the 1970s through the 1990s were reasonably well-designed for their era. You’re not dealing with single-lab preclinical data and Croatian rodent models here. But strong evidence for a fully-characterized approved drug is actually the least interesting kind of strong evidence when you’re trying to identify what to study next.

We don’t see a compelling frontier angle. The anxiolysis mechanism isn’t being revisited in a new light. The H1 space isn’t generating exciting new biology. The drug’s non-controlled status is a clinical feature, not a research opportunity. If your program touches first-gen antihistamines as comparators or pharmacokinetic probes, hydroxyzine is a reasonable tool to have documented. As a primary research target in its own right, honestly, you’re working from a 1956 foundation with nowhere obvious to go.

Novelty

12

Mechanism promise

22

In-category differentiation

32

Evidence quality

68

Translational signal

65

Research bench value

45

Rationale Hydroxyzine scores low on novelty and mechanism because it’s a 70-year-old approved drug with a fully characterized H1/5-HT2A/D2 profile; the high evidence and translational scores reflect its genuine approved-drug trial base, but those can’t rescue the overall when the compound offers nothing a serious investigator hasn’t seen. Bench value gets a modest credit for its canonical probe role comparing CNS-penetrant vs. non-penetrant antihistamine effects via its cetirizine metabolite relationship.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-generation H1 antihistamine anxiolytic

A first-generation piperazine H1 antihistamine with anxiolytic activity; the first non-controlled anxiolytic widely used in psychiatry.

Abstract

Hydroxyzine (2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; CAS 68-88-2; molecular formula C21H27ClN2O2; molecular weight 374.91) is a first-generation piperazine H1 antihistamine developed at UCB and approved by the FDA in 1956 under the trade names Atarax and Vistaril. Distinct from later antihistamines by clinically significant CNS penetration, producing the sedation and anxiolytic effects characteristic of first-generation H1 blockers. H1 affinity approximately 2 nM; secondary 5-HT2A antagonism (Ki approximately 10 nM) and weak D2 antagonism contribute to the anxiolytic profile. The principal active metabolite cetirizine retains H1 antagonism but loses CNS penetration owing to addition of a carboxylic acid group, and is marketed separately as a non-sedating antihistamine (Zyrtec). Plasma half-life is 14 to 25 hours; metabolism is hepatic. Approved for anxiety, pruritus, and as a preoperative sedative; off-label use in insomnia and as a benzodiazepine-sparing anxiolytic. Used as the canonical first-generation H1 antihistamine in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-253Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Gaboxadol (THIP)

Our opinion on this compoundNiche research probe

61/100

The canonical extrasynaptic delta-GABA-A probe; therapeutically abandoned but mechanistically irreplaceable for tonic inhibition research

Look, gaboxadol is a weird one to rate because it exists in two completely separate stories simultaneously. The first story is a clinical failure: Lundbeck and Merck took it through Phase 3 in primary insomnia, watched patients experience disorientation and hallucinations, and pulled the plug in 2007. That story is over. The second story is the interesting one, and its the reason gaboxadol belongs in this library at all.

Here’s the thing about the mechanism. Most GABA pharmacology targets synaptic receptors, the alpha1/2/3-beta-gamma2 isoforms that benzodiazepines and z-drugs hit. Those receptors mediate phasic inhibition, fast transient signals. Gaboxadol does something different: it’s a superagonist at extrasynaptic GABA-A receptors bearing the delta subunit, primarily alpha4-beta3-delta and alpha6-beta3-delta, and those receptors mediate tonic inhibition, the continuous low-amplitude background current that sets the excitability baseline of a neuron. Thats a genuinely different biological variable, and most of the GABA pharmacology toolkit doesn’t let you isolate it cleanly.

We think the differentiation here is underappreciated. Muscimol hits both synaptic and extrasynaptic receptors indiscriminately. DS2, a delta-selective PAM, modulates the receptor but doesn’t agonize it directly. If you want to study what delta-subunit tonic GABA-A current actually does in a circuit, gaboxadol is effectively the only clean pharmacological lever. That’s a real niche, and it’s gotten more interesting since the brexanolone and zuranolone data validated the delta-subunit angle for neurosteroid-sensitive states. Labs working on PMDD biology, alcohol use disorder, stress-related changes in inhibitory tone, or sleep architecture at the subunit level are going to want this compound on the shelf.

The evidence picture is decent for a failed drug. Multiple Phase 3 trials ran to completion before the adverse event signal emerged. That means there’s actual human pharmacology data: real EEG effects, real sleep architecture changes, real CNS penetration confirmed by the adverse events themselves. Preclinical literature is solid and multi-lab. The translational signal is real but it points toward a wall therapeutically, which is why the score here isn’t higher overall.

Honestly, if you’re not working on GABA-A subunit biology specifically, this compound probably isn’t your priority. The clinical failure isn’t a reason to ignore it, but it does mean the research community actively using it is a specialist one. For those investigators, it’s close to indispensable. For everyone else, it’s a footnote in GABA pharmacology history with a genuinely interesting mechanism they probably won’t have occasion to use.

Novelty

48

Mechanism promise

68

In-category differentiation

72

Evidence quality

60

Translational signal

45

Research bench value

75

Rationale Gaboxadol failed Phase 3 as a hypnotic due to adverse psychiatric events, but the mechanism is intact and validated; it scores high on differentiation and bench value because no other compound selectively probes extrasynaptic delta-containing GABA-A receptors with the same precision, making it indispensable for labs working on tonic inhibition, neurosteroid sensitivity, or delta-subunit biology specifically.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective extrasynaptic GABA-A delta-subunit agonist

A 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol agonist selective for extrasynaptic GABA-A receptors containing the delta subunit; investigated as a hypnotic.

Abstract

Gaboxadol (THIP; 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; CAS 64603-91-4; molecular formula C6H8N2O2; molecular weight 140.14) is a selective extrasynaptic GABA-A receptor agonist developed at Lundbeck and Merck through the 1990s and 2000s. Distinct from benzodiazepines and barbiturates by selective binding to GABA-A receptor isoforms containing the delta subunit (alpha4-beta3-delta and alpha6-beta3-delta), which are predominantly extrasynaptic and mediate tonic (continuous, low-amplitude) inhibition rather than the phasic (high-amplitude, transient) inhibition mediated by synaptic alpha1/2/3-beta-gamma2 receptors. The compound is a superagonist at delta-containing receptors (efficacy greater than that of GABA itself). Phase 3 trials in primary insomnia (2007) were halted following adverse psychiatric events including disorientation and hallucinations; development was abandoned. The compound retains research utility as the canonical extrasynaptic delta-GABA-A agonist for academic GABA pharmacology and sleep architecture studies. Plasma half-life is approximately 1.5 to 2 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-255Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tofisopam

Plain-language summaryIntrigue 56 / 100

Tofisopam (Grandaxin) is an unusual benzodiazepine from EGIS in Hungary, registered in the 1960s. The chemistry is technically a benzodiazepine, but the substitution pattern (a 2,3-fused ring rather than the standard 1,4-fused ring of diazepam and lorazepam) means it does not bind the classic GABA-A benzodiazepine site at all. As a result it produces anxiolysis without sedation, muscle relaxation, cognitive impairment, or dependence. The actual mechanism is not fully worked out, with proposals including phosphodiesterase inhibition and dopaminergic modulation. Approved across Europe and parts of Asia for anxiety and autonomic dysfunction; never approved in the US. Genuinely interesting pharmacologically because it shows that the benzodiazepine scaffold can do more than activate GABA-A. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

51/100

A structurally distinct non-GABA-A anxiolytic with real probe value and an incompletely mapped mechanism worth investigating

Here’s the thing about tofisopam: it’s not a benzodiazepine in the way that word usually lands. Yes, the diazepine ring is there, but the nitrogen positions are at the 2,3 carbons rather than the 1,4 positions of diazepam or lorazepam, and that single structural difference eliminates binding at the classical benzodiazepine allosteric site on GABA-A receptors entirely. That means no sedation from GABA current potentiation, no muscle relaxation from that pathway, and by most accounts no physical dependence profile that mirrors classical benzos. EGIS Pharmaceuticals in Hungary developed it in the 1960s, and it’s been marketed as Grandaxin in Hungary, France, and several Asian markets for decades under indications that include anxiety, autonomic instability, and post-stress recovery. For a compound this old to still have an incompletely characterized mechanism is either a red flag or a research opportunity depending on how you look at it.

We lean toward opportunity, cautiously. The leading hypotheses for tofisopam’s activity include phosphodiesterase IV (PDE4) inhibition and some form of dopaminergic modulation, possibly both operating in parallel. PDE4 inhibition is not a trivial mechanism: roflumilast got approved for COPD on that axis, and the neuroimmune and cognitive implications of PDE4 in the CNS have attracted serious attention over the last decade. If tofisopam genuinely hits PDE4 with relevant potency in neural tissue, thats a more interesting story than it usually gets credit for. The dopaminergic angle is less characterized but could explain the reported antifatigue and mood-brightening effects that dont fit a pure anxiolytic profile. What we dont have is a clean pharmacological dissection confirming which target drives which effect at clinically relevant concentrations.

The evidence base is the main drag on the score. Tofisopam has human approval, which is real, but the supporting literature is heavily weighted toward Eastern European clinical work from the 1970s through the 1990s, published in journals that dont make modern replication standards easy to verify. There isnt a modern phase 2 or phase 3 RCT benchmarking it against placebo or active comparators with current methodology. The preclinical literature is sparse compared to what you’d want before building a research program around it.

Where tofisopam earns its keep is as a reference tool. If your lab is trying to understand what non-GABAergic, non-serotonergic anxiolysis looks like pharmacologically, it’s essentially the only 2,3-benzodiazepine with a usable human history and commercial availability. That niche is real but narrow. Honestly, it scores where it scores because it’s genuinely interesting as a probe without being important enough in any active research conversation to rank higher. Investigators in autonomic pharmacology or PDE4 neuroimmunology should know it exists.

Novelty

42

Mechanism promise

55

In-category differentiation

60

Evidence quality

40

Translational signal

48

Research bench value

60

Rationale Tofisopam’s 2,3-benzodiazepine scaffold genuinely sidesteps classical GABA-A activity, making it the reference probe for non-sedating, non-dependence-forming anxiolysis via a mechanism that still isn’t fully nailed down; the European approval provides a real human signal, but the evidence base is dominated by older Eastern European literature with limited modern replication, keeping differentiation and bench value from pulling the score higher.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

2,3-benzodiazepine atypical anxiolytic

A 2,3-benzodiazepine without classical GABA-A activity; a non-sedating anxiolytic marketed in Europe.

Abstract

Tofisopam (1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; CAS 22345-47-7; molecular formula C22H26N2O4; molecular weight 382.46) is a 2,3-benzodiazepine developed at EGIS (Hungary) in the 1960s and approved in Hungary, France, and other European and Asian markets under the trade name Grandaxin. Distinct from the 1,4-benzodiazepine class (diazepam, lorazepam, etc.) by the position of the nitrogens in the diazepine ring: the 2,3 isomer does not bind the classical benzodiazepine site on GABA-A receptors and lacks the GABA-A-mediated sedation, anxiolysis, and dependence of conventional benzodiazepines. The mechanism is incompletely characterized; possibilities include phosphodiesterase IV inhibition and modulation of dopaminergic signaling. Plasma half-life is approximately 6 to 8 hours; metabolism is hepatic. Approved indications in markets where registered include anxiety disorders, autonomic instability, and post-stress recovery; off-label use in fatigue and reactive depression. Not approved in the US. Used as a reference 2,3-benzodiazepine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-254Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Propranolol

Plain-language summaryIntrigue 73 / 100

Propranolol (Inderal) is the first commercially successful beta-blocker, developed by James Black at ICI and approved by the FDA in 1967. Black’s work on it earned him the Nobel Prize and reshaped cardiovascular medicine. It blocks both subtypes of beta-adrenergic receptor, dampening the heart’s response to adrenaline as well as the bronchial and metabolic effects. Beyond its many cardiovascular uses, it has a substantial second life in psychiatry and neurology: it is the standard prescription for performance anxiety (one or two tablets before public speaking blunts the heart-pounding and tremor without affecting cognition), is first-line for migraine prevention, and has been studied for trauma memory reconsolidation in PTSD. Lipophilic enough to cross into the brain, which contributes to both its therapeutic and side effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Historical cornerstone with almost no remaining research novelty; valuable as a canonical non-selective beta-blocker probe

Look, propranolol is one of the most consequential drugs in the history of pharmacology. James Black’s Nobel Prize was built partly on it. And yet, as a research target in 2026, it’s almost entirely spent. That’s the tension the score reflects, and it’s not a close call.

The cardiovascular evidence base is airtight. Hypertension, angina, atrial fibrillation, migraine prophylaxis, essential tremor — six approved indications and decades of replicated RCTs sitting behind each of them. The pharmacokinetics have been characterized exhaustively: non-selective beta-1 and beta-2 blockade, 3-to-6 hour half-life, high lipophilicity giving CNS penetration that hydrophilic competitors like atenolol and nadolol simply lack. Those properties earned it permanent status as the reference non-selective beta-blocker. That reference-compound identity is essentially its only remaining research value — real, but narrow.

The most interesting live research angle is the PTSD memory reconsolidation work, and we want to be honest about what that actually is. The mechanistic logic is genuinely clever: noradrenergic signaling in the basolateral amygdala is required for fear memory reconsolidation, so blocking beta-adrenergic receptors during a deliberate recall event should attenuate reconsolidation and weaken the traumatic memory. Pitman’s Harvard MGH group published the original proof-of-concept in 2002. Alain Brunet’s Montreal lab has been the most persistent investigator, including a 2018 randomized trial in PTSD patients showing meaningful symptom reduction. The signal is real. But the 2019 Cochrane review found the evidence base insufficient, effect sizes across studies are modest, and its been 24 years since the founding paper. Calling this novel would be a stretch.

The novelty problem is fundamental. Beta-adrenergic blockade has been understood mechanistically since the 1960s. No new chemistry, no new mechanisms, no structural innovations. For reconsolidation paradigms specifically, metoprolol covers most of the same ground, and timolol is another option with similar CNS access. Propranolol has first-mover advantage in this niche and a denser associated literature, but its not uniquely irreplaceable in most bench designs.

What we like: the translational track record is definitive, and for performance anxiety studies, adrenergic probe work, or reconsolidation paradigms, its the right tool and the right reference. What we don’t like: the mechanism is fully characterized, the novelty is gone, and the questions propranolol can uniquely answer are getting fewer every year. A serious investigator building a new research program around propranolol in 2026 would need a very specific reason. This is a historical cornerstone, not a frontier compound.

Novelty

10

Mechanism promise

20

In-category differentiation

30

Evidence quality

80

Translational signal

80

Research bench value

50

Rationale Propranolol scores extremely low on novelty and mechanism — it’s a 1967 drug with single-receptor, fully-characterized pharmacology and no new chemistry — but pulls evidence and translational scores high owing to its approved-drug status across six indications and 60 years of clinical use; the PTSD memory reconsolidation angle is the most interesting current research use case, but Pitman’s foundational work is 24 years old and replication remains mixed, preventing a meaningful novelty rescue.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-selective beta-adrenergic antagonist

A non-selective beta-adrenergic antagonist; the first beta-blocker, repurposed for performance anxiety and migraine prophylaxis.

Abstract

Propranolol (1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 525-66-6; molecular formula C16H21NO2; molecular weight 259.34) is a non-selective beta-adrenergic antagonist developed by James Black at ICI and approved by the FDA in 1967 under the trade name Inderal. The compound is the first commercially successful beta-blocker, foundational to modern cardiovascular pharmacology. Beta-1 affinity is approximately equal to beta-2 affinity (non-selective). Plasma half-life is 3 to 6 hours; the lipophilic structure produces high CNS penetration, distinguishing propranolol from hydrophilic beta-blockers (atenolol, nadolol) for indications requiring central effect. Approved indications include hypertension, angina, atrial fibrillation, migraine prophylaxis, essential tremor, and hypertrophic cardiomyopathy. Off-label use is extensive: performance anxiety (most common psychiatric indication), PTSD memory reconsolidation, akathisia, hyperthyroid tachycardia. The 5-HT receptor partial agonism (weak) was a former curiosity but is not clinically meaningful at standard doses. Used as the canonical non-selective beta-blocker reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-256Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pindolol

Plain-language summaryIntrigue 48 / 100

Pindolol is an old beta-blocker, FDA-approved in 1982, that lowers blood pressure by quieting the heart. What makes it interesting outside cardiology is a side activity: it binds tightly to a serotonin receptor (5-HT1A) that normally throttles serotonin release. By turning off that throttle alongside an SSRI antidepressant, pindolol was hypothesized to make the SSRI kick in faster (days rather than weeks). Trials produced mixed results, with some studies showing accelerated response in depression and others showing nothing. It is still used occasionally in psychiatry as an SSRI booster, but never became standard practice. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

37/100

Old beta-blocker with real 5-HT1A probe value, but inconsistent clinical signal limits excitement

Look, pindolol is one of those compounds where the mechanism is more interesting than the compound itself. Approved for hypertension in 1982, it spent years as a fairly unremarkable non-selective beta-blocker until researchers noticed something: it binds 5-HT1A receptors with real affinity (Ki around 50 nM) and acts as a partial agonist there. That property got it drafted into psychiatric research as an SSRI augmentor in the 1990s, and for a while it was genuinely intriguing.

The hypothesis was elegant. SSRIs lose their first two weeks to autoreceptor-mediated negative feedback at the raphe. Add a 5-HT1A partial agonist like pindolol, and you desensitize those presynaptic autoreceptors faster, in theory compressing the latency to antidepressant effect. Multiple placebo-controlled trials tested this through the late 1990s and into the 2000s. Some showed a real 1-2 week acceleration. Others did not. The meta-analyses are frustrating reading: positive signal on onset, weaker or null signal on overall efficacy. That inconsistency is the core problem with this compound as a research target, and we think it explains why the field mostly moved on.

Where pindolol still earns its place in a serious library is as a probe. Its specific combination of beta-blockade plus 5-HT1A partial agonism is hard to replicate with other tools. If you’re running mechanistic work on presynaptic serotonin autoreceptor desensitization, or trying to parse the cardiovascular from the serotonergic components of a drug interaction, pindolol gives you a handle thats difficult to replace. Its been called the canonical 5-HT1A binding beta-blocker in mechanism studies for good reason. Buspirone is more selective at 5-HT1A but lacks the beta component entirely. That combination makes pindolol genuinely useful for dissecting receptor contributions in mixed-pharmacology contexts.

What we dont love: the SSRI augmentation question is basically settled as disappointing, the compound is old enough that most interesting questions about it have been asked, and the short half-life (3-4 hours) is a practical nuisance in research designs. Its not a novel mechanism, not a novel compound, and the translational arrow from preclinical to clinical is pointing in different directions depending on which trial you read.

Honestly, if youre building a research program around serotonin autoreceptor biology and need a pharmacological tool with a specific dual profile, pindolol is worth having. As a primary research target in its own right? The case is thin. The probe utility is real but narrow, and the clinical inconsistency means the translational story never really closed.

Novelty

20

Mechanism promise

42

In-category differentiation

35

Evidence quality

45

Translational signal

35

Research bench value

52

Rationale Pindolol scores as a niche probe because its 5-HT1A autoreceptor work is genuinely useful for serotonin pharmacology, but the compound is a 1982 FDA approval with mixed augmentation trial data; bench utility saves it from obscurity, novelty and translational inconsistency drag the overall down.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-selective beta-adrenergic antagonist with 5-HT1A partial agonism

A non-selective beta-blocker with intrinsic 5-HT1A partial agonism; investigated as an SSRI augmenting agent.

Abstract

Pindolol (1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 13523-86-9; molecular formula C14H20N2O2; molecular weight 248.32) is a non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonism) and 5-HT1A partial agonism, approved by the FDA in 1982. The compound’s distinguishing pharmacological feature in psychiatric research is high-affinity 5-HT1A binding (Ki approximately 50 nM) with partial agonist activity at presynaptic autoreceptors; concurrent administration with an SSRI desensitizes the autoreceptor more rapidly than the SSRI alone, hypothetically accelerating the antidepressant response. Multiple placebo-controlled trials in the 1990s and 2000s reported faster onset (1 to 2 weeks shorter latency) but inconsistent overall efficacy improvement. Plasma half-life is 3 to 4 hours; metabolism is hepatic. Approved indications in cardiology include hypertension and angina; the SSRI augmentation use remains off-label. Used as the canonical 5-HT1A binding beta-blocker in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-257Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Clonidine

Plain-language summaryIntrigue 60 / 100

Clonidine is a 1960s blood-pressure drug (sold as Catapres) that turned out to be unexpectedly versatile. It works by activating alpha-2 adrenergic receptors in the brainstem, dampening the sympathetic nervous system, the body’s stress response. That single mechanism explains why it lowers blood pressure, blunts opioid withdrawal symptoms, calms tics in Tourette syndrome, and reduces hyperactivity in ADHD (often as a non-stimulant alternative or add-on to stimulants in children). It is also used to manage hot flashes and as a sedating premedication. The drug is cheap, generic, and well-characterized, with sedation and rebound hypertension on abrupt discontinuation as the main downsides. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

45/100

Prototype alpha-2 agonist with real bench utility but essentially zero research novelty

Look, clonidine is not a research compound in any contemporary sense of the word. Boehringer Ingelheim synthesized it in the 1960s looking for a nasal decongestant, stumbled onto a central antihypertensive, and the FDA approved it in 1974. That backstory tells you a lot about where this thing sits in 2025: its mechanism was characterized before most of today’s investigators were born, and the pharmacology has not moved since.

The mechanism is presynaptic alpha-2A autoreceptor activation in the locus coeruleus, which dials down central noradrenergic tone. Secondary imidazoline I1 activity contributes to the blood pressure effect. Both of those stories are closed chapters in the literature. Theres nothing here that opens a new question; every pathway clonidine touches has been characterized to death, and the interesting molecular biology has moved to more selective tools. Dexmedetomidine is far more alpha-2A selective. Guanfacine has a cleaner CNS profile and is now the preferred agent for ADHD in most treatment algorithms. In differentiation terms, clonidine is the prototype that got superseded.

Where we do give clonidine some credit is bench utility. It remains the canonical alpha-2 reference standard for studies of noradrenergic regulation, locus coeruleus physiology, and sympathetic nervous system modulation. If you’re designing a study that needs a clean alpha-2 agonist as a positive control or pharmacological probe, clonidine is still what most labs reach for, partly because the literature comparator base is enormous. The PTSD-associated hyperarousal work, particularly the fear consolidation studies out of Pitman and Cahill’s groups, used clonidine as the reference intervention precisely because any new agent has to beat a known standard. That kind of indispensable-comparator role keeps the bench value score from cratering.

The translational and evidence scores are the only numbers that look strong here, and honestly they should, because this is an approved drug with decades of clinical use across four labeled indications. The rebound hypertension on abrupt discontinuation is one of the best-characterized discontinuation effects in all of pharmacology. But evidence quality for a research library score is about how much we’ve learned, not how much we’ve confirmed; at this point clonidine is all confirmation, no discovery.

We think this compound belongs in the library as a reference entry, not as something an investigator would build a program around in 2025. The score of 45 reflects that: real clinical and bench-utility credit, close-to-zero novelty and mechanism credit. Use it as the comparator arm, not the experimental arm.

Novelty

18

Mechanism promise

28

In-category differentiation

35

Evidence quality

78

Translational signal

72

Research bench value

65

Rationale Clonidine scores moderate overall on the strength of its well-validated clinical record and genuine utility as the reference alpha-2 agonist in noradrenergic research, but novelty and mechanism scores drag hard because this is a 1960s compound with a fully mapped single-receptor mechanism; more selective successors like dexmedetomidine and guanfacine have largely displaced it in both clinic and bench contexts.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Central alpha-2 adrenergic agonist

An imidazoline alpha-2 adrenergic receptor agonist; an antihypertensive repurposed for ADHD, opioid withdrawal, and Tourette syndrome.

Abstract

Clonidine (N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; CAS 4205-90-7; molecular formula C9H9Cl2N3; molecular weight 230.10) is an imidazoline alpha-2 adrenergic agonist developed at Boehringer Ingelheim in the 1960s and approved by the FDA in 1974 under the trade name Catapres. The compound activates presynaptic alpha-2A adrenergic autoreceptors in the locus coeruleus, reducing central noradrenergic outflow and producing centrally mediated reductions in sympathetic tone, blood pressure, and heart rate. Secondary imidazoline I1 receptor activity contributes to the antihypertensive effect. Plasma half-life is 12 to 16 hours; renal excretion is the principal clearance pathway. Approved indications include hypertension, ADHD (extended-release Kapvay), opioid withdrawal, and Tourette syndrome; off-label use in insomnia, hot flashes, and PTSD-associated hyperarousal. Rebound hypertension on abrupt discontinuation is a characteristic adverse effect. The compound is widely used in academic neuroscience as the prototype alpha-2 agonist for studies of noradrenergic regulation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-258Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vinpocetine

Plain-language summaryIntrigue 50 / 100

Vinpocetine (Cavinton) is a synthetic alkaloid derived from vincamine in the lesser periwinkle plant, developed at Gedeon Richter in Hungary in the 1960s. Approved across Europe for cerebrovascular insufficiency and used as a nootropic in the US (sold as a supplement). It works through several mechanisms at once: cerebral vasodilation, weak phosphodiesterase 1 inhibition, neuronal sodium channel block, and modest antioxidant activity, with the combined effect of improving blood flow to the brain. Clinical evidence in cognitive impairment and stroke recovery is mixed and dominated by older Eastern European trials with weak methodology. The FDA flagged it in 2019 over concerns about miscarriage in pregnant users. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

32/100

A 1960s cerebrovascular workhorse with weak PDE1 inhibition that has been surpassed by more selective modern tools

Vinpocetine is one of those compounds that was genuinely interesting in 1975 and has been coasting on that reputation ever since. Developed at Gedeon Richter in Hungary as a synthetic derivative of vincamine, it got approval across Eastern Europe under the Cavinton trade name and built up a moderately sized clinical literature, mostly through the 1980s and 1990s. That history is real. The problem is that the research has barely moved since.

The mechanism is pluripotent in the way that usually signals we don’t really know what’s driving the effect. PDE1 inhibition is the most cited angle, and it’s not a bad one; PDE1B and PDE1C have legitimate neurological relevance, and the cyclic nucleotide signaling cascade downstream is genuinely interesting biology. But vinpocetine’s PDE1 affinity is weak relative to selective inhibitors that came later. The cerebrovascular vasodilation story is real but not mechanistically novel. The sodium channel block exists but is modest. What you end up with is a compound that does several things modestly well rather than one thing exceptionally.

Differentiation is where vinpocetine struggles most against modern alternatives. If you’re interested in PDE1 specifically, ITI-214 (now lenrispodun) is a selective, high-affinity PDE1 inhibitor with clean human pharmacology data and a phase 2 trial in heart failure. If you want cerebrovascular effects, the field has largely moved to better-characterized agents. Vinpocetine competes with neither, and its FDA story is awkward: the agency has questioned whether it legally qualifies as a dietary supplement given its pharmaceutical development history, which creates a real sourcing ambiguity for US-based research programs.

The evidence base is an honest moderate score. There’s a multi-decade literature, some small RCTs in European populations, and a Cochrane review that found evidence insufficient to support use in dementia. Not nothing. But a lot of the primary literature comes from Eastern European groups with methodological standards that dont hold up well against modern expectations, and independent replication from Western labs is sparse. The translational signal exists, it’s just not compelling by current standards.

We think vinpocetine still has marginal utility as a rough PDE1 inhibitor tool in preclinical CNS work, particularly when selectivity isn’t the priority and broad cerebrovascular modulation is the goal. Thats a narrow use case. For investigators seriously studying PDE1 biology, ITI-214 is the right probe. For cerebrovascular research, the compound landscape looks very different in 2025 than it did when Cavinton was approved. Vinpocetine is a historical artifact that still holds a slot in the library, but serious bench scientists should know what they’re not getting when they reach for it.

Novelty

20

Mechanism promise

32

In-category differentiation

28

Evidence quality

45

Translational signal

40

Research bench value

35

Rationale Developed in the 1960s with a multi-decade Eastern European clinical literature, vinpocetine’s pluripotent-but-weak mechanism and poor differentiation against selective modern PDE1 inhibitors keep novelty and differentiation scores low; evidence quality is moderate given the Cochrane-reviewed RCT base, but independent Western replication is sparse and effect sizes are modest throughout.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic vincamine derivative / cerebrovascular agent

A synthetic alkaloid derivative of vincamine from Vinca minor; a cerebrovascular agent and PDE1 inhibitor used as a nootropic.

Abstract

Vinpocetine ((3-alpha,16-alpha)-eburnamenine-14-carboxylic acid ethyl ester; CAS 42971-09-5; molecular formula C22H26N2O2; molecular weight 350.46) is a synthetic alkaloid derivative of vincamine from Vinca minor (lesser periwinkle), developed at Gedeon Richter (Hungary) in the 1960s and approved in many European countries as Cavinton for cerebrovascular insufficiency. Mechanism is multifactorial: cerebral vasodilation through smooth muscle relaxation, weak phosphodiesterase 1 (PDE1) inhibition, sodium channel block in neurons, and modest antioxidant activity. The combined effect produces improved cerebral blood flow and reduced ischemic neuronal injury in animal stroke models. Plasma half-life is approximately 1 to 2 hours; metabolism is hepatic via CYP2C9 and CYP3A4. Approved indications in Europe include cerebrovascular disorders, age-related cognitive decline, and tinnitus. In the US, the compound is sold as a dietary supplement with FDA reservations about that designation given its drug-like history. Used as a cerebrovascular nootropic and PDE1 inhibitor in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-305Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vincamine

Plain-language summaryIntrigue 35 / 100

Vincamine is the natural indole alkaloid extracted from Vinca minor (lesser periwinkle), the parent compound that vinpocetine was derived from. It shares the cerebral-vasodilation and modest phosphodiesterase-inhibition profile with vinpocetine but is shorter-acting and less lipophilic. Approved in France (as Pervincamine) and Italy for cerebrovascular insufficiency and mild dementia. Largely supplanted by vinpocetine in markets where both are available, owing to the latter’s better pharmacokinetics. Of mainly historical interest as the natural starting point for the eburnane vasodilator class. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

Parent compound of vinpocetine; superseded by its own derivative with limited independent research value

Look, vincamine occupies a specific and somewhat awkward position in the research landscape: it’s the parent compound of vinpocetine, which means its most important historical contribution was getting chemically modified into something better. That’s not a great story for a research target in 2026.

The mechanism isn’t the issue per se. Cerebral vasodilation via smooth muscle relaxation, mild PDE inhibition, some antioxidant activity in mitochondrial fractions. These are real biological effects, but they’re not novel and have been well-characterized for decades. France approved it as Pervincamine; Italy uses it for cerebrovascular insufficiency and age-related cognitive decline. That approval history gives it more clinical anchoring than most peptides on research shelves, which is something. But the underlying mechanism class has had a rough few decades in terms of clinical translation for dementia-adjacent indications, and vincamine specifically isn’t a bright spot in that story.

The differentiation problem is hard to argue around. Vinpocetine is more lipophilic, crosses the blood-brain barrier more efficiently, has a longer half-life (roughly 2-3 hours vs vincamine’s approximately 1 hour), and carries substantially more published literature from independent groups. If you’re asking a bench-level question about the eburnane alkaloid scaffold, vincamine is the historical reference; it’s not the compound you’d choose to answer that question with today. The derivative wins almost every comparison you’d care about.

Thats not to say vincamine is worthless. For labs doing comparative scaffold chemistry, looking at the eburnane core versus its semisynthetic variants, vincamine is the natural starting material and the reference point. There’s legitimate synthetic and pharmacokinetics work where having the parent compound matters. We also think the European approved-drug status means the safety and tolerability file is cleaner than for most research compounds in this space, and the multi-decade literature gives you methodological precedent to work from.

What we don’t like is how little of that literature is modern, replicated by independent groups, or aimed at anything beyond the fairly ill-defined category of cerebrovascular insufficiency, an indication the field has largely moved away from. Most of the published clinical work predates 2000 and is of variable methodological quality by current standards.

Honestly, if you’re building out an eburnane scaffold comparative program, vincamine belongs in the collection as a reference compound. For any other purpose, the resource allocation case is weak. Vinpocetine does what vincamine does, only better, which is a hard position to argue your way out of.

Novelty

22

Mechanism promise

27

In-category differentiation

18

Evidence quality

38

Translational signal

40

Research bench value

32

Rationale Vincamine scores poorly on novelty and differentiation because it’s a decades-old European-approved cerebrovascular agent whose semisynthetic derivative outperforms it on nearly every pharmacokinetic and research-utility dimension; evidence quality is modest given the largely pre-modern clinical literature, and the mechanism is unremarkable cerebrovascular dilation plus weak PDE inhibition.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Periwinkle alkaloid / cerebrovascular agent

An indole alkaloid from Vinca minor; the parent compound of vinpocetine, used as a cerebrovascular agent in Europe.

Abstract

Vincamine ((3-alpha,14-beta,16-alpha)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester; CAS 1617-90-9; molecular formula C21H26N2O3; molecular weight 354.45) is an indole alkaloid isolated from Vinca minor (lesser periwinkle). The compound is the natural precursor of vinpocetine, sharing the eburnane scaffold but with reduced lipophilicity and shorter duration of action. Mechanism: cerebral vasodilation, modest PDE inhibition, antioxidant activity. Approved in several European countries (notably France as Pervincamine and Italy) for cerebrovascular insufficiency, mild dementia, and age-related cognitive decline. Plasma half-life is approximately 1 hour; oral bioavailability is moderate. Used as a cerebrovascular agent in academic research and as the historical reference compound for the eburnane class.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-306Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Hydergine (Ergoloid Mesylates)

Our opinion on this compoundEstablished workhorse

28/100

Historical ergoloid mixture with diffuse mechanism, inconsistent modern evidence, and no competitive angle against current alternatives

Look, Hydergine has a genuinely interesting pedigree. Albert Hofmann developed it at Sandoz in the 1940s, and for several decades it was among the most-prescribed drugs on the planet for age-related cognitive decline. That history matters as context. But historical ubiquity and research merit in 2026 are very different things, and Hydergine scores low here for reasons that get clearer the closer you look.

The pharmacology is honestly a mess. It’s a fixed mixture of four dihydrogenated ergoloid alkaloids in a 3:3:2:1 ratio, and the proposed mechanisms read like a catalog of everything researchers thought might matter in 1965: alpha-adrenergic antagonism, weak dopaminergic and serotonergic modulation, some effect on neuronal energy metabolism, and antioxidant activity the abstract itself describes as weak. None of that is factually wrong. But none of it is a crisp pharmacological hypothesis either. You’re not probing a defined receptor system with a selective tool; you’re applying a multi-component ergoloid mixture to a preparation and watching a diffuse readout. The mechanism being incompletely characterized after 70-plus years of use is not a sign of deep mystery worth investigating. It’s a sign the signal was never clean enough to resolve.

The evidence picture is even harder to defend. Cochrane-style systematic reviews of Hydergine for dementia and cognitive decline have repeatedly returned inconsistent benefit, with effect sizes that are modest at best and unreliable across trials. This isnt a compound that lost a fair fight to superior competitors. It’s a compound whose initial approvals predated rigorous RCT design, and when methodology improved, the signal did not hold up. Cholinesterase inhibitors and memantine have replaced it in clinical practice for well-documented reasons, and no serious dementia or cognitive aging program is anchored on ergoloid alkaloids today.

Differentiation is essentially negative. On every dimension that matters for a 2026 research program, Hydergine is outclassed: cleaner mechanism compounds exist for each of its proposed targets individually, and the multi-target case is weaker than it looks because the components were not rationally combined for synergy.

What we think: the only realistic bench use-case is as an ergoloid reference standard for comparative alkaloid pharmacology or for historical context in nootropic mechanism reviews. That keeps bench value from hitting the floor entirely, but it doesnt rescue the compound as an active research target. The frontier has moved well past it.

Novelty

20

Mechanism promise

28

In-category differentiation

20

Evidence quality

42

Translational signal

30

Research bench value

38

Rationale Developed in the 1940s and once globally ubiquitous, Hydergine’s multifactorial mechanism remains incompletely characterized and modern systematic reviews return inconsistent cognitive benefit; it has been supplanted clinically by cholinesterase inhibitors and retains only narrow ergoloid reference value for bench work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Ergoloid mixture (dihydroergocornine, dihydroergocristine, dihydroergocryptine)

A mixture of dihydrogenated ergoloid alkaloids; used historically for cognitive decline and as a senescence-associated nootropic.

Abstract

Hydergine (codergocrine mesylate; CAS 8067-24-1; mixture of dihydroergocornine, dihydroergocristine, and dihydroergocryptine alpha and beta isomers in 3:3:2:1 ratio; molecular weight approximately 660 to 700 Da) is a mixture of dihydrogenated ergoloid alkaloids developed at Sandoz (now Novartis) by Albert Hofmann in the 1940s. The compound was approved for senescence and senile mental status in many countries from the 1950s onward; it was once among the most prescribed drugs globally. Mechanism is multifactorial and incompletely characterized: alpha-adrenergic antagonism, dopaminergic and serotonergic effects, modulation of neuronal energy metabolism, and weak antioxidant activity. Modern systematic reviews have produced inconsistent evidence of cognitive benefit; the compound is largely supplanted in clinical practice by cholinesterase inhibitors and memantine for dementia. Plasma half-life is approximately 5 hours. Used as a historical nootropic and ergoloid reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-307Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cinnarizine

Plain-language summaryIntrigue 42 / 100

Cinnarizine is a 1970s Janssen compound that hits multiple targets at once: T-type calcium channels (cerebrovascular dilation, vestibular nerve effects), H1 histamine receptors (antihistamine), and weakly D2 dopamine receptors. The combined activity makes it useful for vertigo, motion sickness, and cerebrovascular insufficiency. Approved across Europe and Asia, never in the US. The D2 antagonism produces a small but real risk of drug-induced parkinsonism with long-term use, especially in elderly patients, which has limited enthusiasm. The motion sickness use is well-established. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

A 1970s multi-target CCB/antihistamine with narrow vestibular probe value but little frontier appeal

Look, cinnarizine is a 1970s Janssen compound that does several things reasonably well and none of them in a way thats particularly exciting to a researcher in 2026. T-type voltage-gated calcium channel inhibition, H1 antihistamine activity, and weak D2 dopamine receptor antagonism: that’s a multi-target profile, which sounds interesting until you realize all three arms of it are thoroughly mapped territory. There is no live mechanism question here.

The T-type CCB angle is the most research-interesting piece. T-type channels have gotten real attention in chronic pain, absence epilepsy, and cardiovascular biology, and cinnarizine functioned as a workable probe before more selective tools like Z944 or NCC-55-0396 came along. But “was useful before better tools existed” isn’t the same as “is useful now.” For anyone doing serious T-type channel work in 2026, cinnarizine’s selectivity profile is a liability. You’re blocking H1 and touching D2 whether you want to or not, which means you’re not probing T-type channels; you’re running a three-target pharmacology experiment with only partial control over two of the targets.

The vestibular pharmacology angle is where cinnarizine holds its remaining bench value. It’s a reference compound in that space, and if your program touches labyrinthine calcium dynamics or vestibular compensation, its approved clinical status in Europe gives you a reasonable phenotype-to-compound anchor. The evidence base is real: multi-decade literature, regulatory approval in EU and Asia, clear clinical signal in vertigo and motion sickness populations. That said, the original approval trials are not by modern methodological standards, and the cerebrovascular insufficiency indication sits on softer ground than the vestibular work.

The D2 antagonism is genuinely problematic from a research design perspective. It’s not an asset; it’s a confounder. Any experiment where dopaminergic tone matters gets complicated by the fact that you’re running a mild D2 blocker alongside whatever else you’re studying. In aged animal models especially, the extrapyramidal liability is a real concern that limits translational utility. Its US non-approval is sometimes cited as intrigue, but honestly it reflects nothing more than a risk calculus applied to a compound that doesn’t offer anything a US investigator can’t get from more selective tools.

We don’t think cinnarizine is junk. For narrow vestibular or inner-ear calcium dynamics studies, it retains genuine reference value, and the multi-target profile produces interpretable pharmacology when you specifically want simultaneous vascular and histamine pathway modulation. But this is a 50-year-old drug whose mechanism is fully characterized, whose indications are well-served by existing data, and whose research frontier was crossed a long time ago. A bench scientist centering a 2026 program on cinnarizine is probably reconstructing history rather than generating it.

Novelty

22

Mechanism promise

38

In-category differentiation

38

Evidence quality

52

Translational signal

58

Research bench value

44

Rationale Cinnarizine is a fully characterized 1970s Janssen compound whose T-type CCB/H1/weak-D2 profile is thoroughly mapped; bench value is real but narrow (vestibular pharmacology reference use), novelty is minimal, and the D2 confounder limits clean experimental design in most modern research programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Diphenylmethyl-piperazine calcium channel blocker / antihistamine

A diphenylmethyl-piperazine T-type calcium channel blocker with antihistamine activity; used for vertigo, motion sickness, and cerebrovascular disease.

Abstract

Cinnarizine (1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; CAS 298-57-7; molecular formula C26H28N2; molecular weight 368.52) is a diphenylmethyl-piperazine multi-target compound developed at Janssen and approved in many European and Asian markets in the 1970s. Mechanism: T-type voltage-gated calcium channel inhibition (cerebrovascular dilation, vestibular nerve effects), H1 antihistamine activity, and weak D2 dopamine receptor antagonism. The combined activity supports use in vestibular disorders, motion sickness, and cerebrovascular insufficiency. The D2 antagonism produces a small but real risk of extrapyramidal side effects (parkinsonism, tardive dyskinesia) with long-term use, particularly in elderly patients; this has limited use in some jurisdictions. Plasma half-life is approximately 4 hours. Approved for vertigo, motion sickness, and cerebrovascular disease in EU and Asia; not approved in the US. Used as a multi-target reference compound for vestibular pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-309Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 57 58 59 60 61 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.